Roche enters agreement with drug discovery company

Roche has entered an agreement with genomics-based drug discovery company Galapagos’s service division, BioFocus.

The deal will see BioFocus supply the Swiss-based pharmaceutical company with exclusive chemical compound libraries, based on Roche’s structures.

“We are very pleased with this new agreement to deliver exclusive compound libraries to complement Roche’s drug discovery programmes,” said Onno van de Stolpe, chief executive officer of Galapagos.

“With a strong set of design tools and world-class synthetic chemistry capabilities, BioFocus continues to secure new business by providing high-quality libraries to the pharmaceutical and biotech industries.”

The three-year agreement is an extension of what Galapagos refers to as a “successful working history” between Roche and BioFocus.

Galapagos is partnered with a number of big-name pharmaceutical companies, including AstraZeneca, GlaxoSmithKline, Novartis and Wyeth. It has facilities in Belgium, the Netherlands and the UK and employs more than 200 people.

© Adfero Ltd